Stay informed about the latest breakthroughs in clinical research, FDA approvals, and healthcare innovation.
Houston, Cleveland, and Seattle have dense research sites and live Corterve community pages. This metro guide shows how to read location lists, with catalog examples from lung, heart device, and endometrial studies.
People with type 2 diabetes often ask how trials differ from regular care, why a search returns mixed studies, and who decides eligibility. This draft answers those questions with live public records.
Learn how to search lung cancer clinical trials by type, biomarker, phase, and city. This guide uses live ClinicalTrials.gov records and listed U.S. catalog examples. It is not medical advice.
A first-in-class BTK degrader (BGB-16673) is recruiting across 31 US sites for relapsed/refractory B-cell malignancies including CLL, MCL, WM, MZL, FL, and DLBCL. The CaDAnCe-101 trial (NCT05006716) offers a novel mechanism to overcome covalent BTK inhibitor resistance.
High drop-out rates delay vital drug approvals. Discover actionable strategies to maximize patient engagement and build long-term trust in clinical research.
Discover how shifting the focus toward patient centricity is transforming clinical trial design, accelerating recruitment, and improving retention rates.
A comprehensive guide to the questions you should ask and factors to consider when evaluating a clinical trial opportunity, including new FDA expedited pathways.
In 2025, the FDA approved 46 novel drugs. Learn how Phase 3 trials work and why they're the crucial final step before a treatment reaches patients.
Why diverse participation matters for medical research, how it impacts treatment outcomes, and what researchers are doing to make trials more inclusive.
Several highly anticipated weight loss treatments are pending FDA approval, including oral GLP-1 drugs like orforglipron that could offer more accessible alternatives to injectables.
Artificial intelligence is transforming how patients find clinical trials, analyzing vast datasets for personalized matching and accelerating the path to new treatments.
The FDA has approved suzetrigine, the first non-opioid pain medication for moderate-to-severe acute pain, addressing a critical need for non-addictive pain management alternatives.
Revolutionary gene-editing platforms developed by researchers are enabling custom gene editing for rare metabolic disorders, representing significant strides in genetic medicine.
Yeztugo (lenacapavir), a revolutionary twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), has been approved, offering a significant advancement in AIDS prevention.
Our articles cite their sources. We do not claim affiliation with FDA, NIH, Harvard Medical School, or other institutions. Educational content is not medical advice.
Talk with us about studies, sites, or educational content. We do not send unsolicited recruitment email.
Talk with usWe respect your privacy. Patient contact follows consent.
